Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 9/20 | 1.00 |
| ▸ | ITPR1 | Q14643 | 5/20 | 1.00 |
| ▸ | ITPR2 | Q14571 | 4/20 | 1.00 |
| ▸ | INPP5A | Q14642 | 2/20 | 1.00 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.90 |
| ▸ | AKT1 | P31749 | 1/20 | 0.90 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ins(1,4,5)P3 SCHEMBL9383914 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL4871682 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL28087353 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL9382320 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL98182 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL10490812 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL381458 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL382820 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL4874594 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL19532798 | 0.94 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4275705-B1 | PANCREATITIS TREATMENT | CALCIMEDICA INC (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | disclosed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118871110-A | Methods and compositions for treating inflammatory lesions of the lung | 钙医学公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20240307384-A1 | PYRAZINE-CONTAINING COMPOUND | CALCIMEDICA, INC. | 2024-09-19 | — | — | US | disclosed |
| US-11905248-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| EP-4275705-A2 | PANCREATITIS TREATMENT | Calcimedica, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11752148-B2 | Pyrazine-containing compound | CALCIMEDICA, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| EP-0748210-B1 | METHODS OF USING CYCLIC POLYANIONIC POLYOL DERIVATIVES FOR REGULATING SKIN WRINKLES | PROCTER & GAMBLE (US) | 1999-07-14 | — | — | EP | disclosed |
| WO-1999007339-A1 | COMPOSITIONS FOR VISUALLY IMPROVING SKIN | THE PROCTER & GAMBLE COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
| US-5821237-A | ACTIVE MATERIALS CONTAIN AT LEAST ONE CYCLIC POLYANIONIC POLYOL, AT LEAST ONE SULFYDRYL COMPOUND AND AT LEAST ONE ZWITTERIONIC SURFACTANT | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0748210-A1 | METHODS OF USING CYCLIC POLYANIONIC POLYOL DERIVATIVES FOR REGULATING SKIN WRINKLES | THE PROCTER & GAMBLE COMPANY (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995023588-A1 | METHODS OF USING CYCLIC POLYANIONIC POLYOL DERIVATIVES FOR REGULATING SKIN WRINKLES | THE PROCTER & GAMBLE COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| US-5434144-A | Methods of using cyclic polyanionic polyol derivatives for regulating skin wrinkles | THE PROCTER & GAMBLE COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| US-4755612-A | Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol | MERCK & CO., INC. (US) | 1988-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11752148-B2 | Pyrazine-containing compound | NFATC1, IAPP, NLRP3 | ITPR3 30/4885ITPR1 28/4885ITPR2 35/4885 |
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | ORAI1, MAVS, CASR | ITPR3 354/4885ITPR1 195/4885ITPR2 236/4885 |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | IL1B, MAVS, MMP8 | ITPR3 159/4885ITPR1 136/4885ITPR2 179/4885 |
| US-11905248-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | ITPR3 62/4885ITPR1 58/4885ITPR2 45/4885 |
| US-20240307384-A1 | PYRAZINE-CONTAINING COMPOUND | NFATC1, IAPP, NLRP3 | ITPR3 30/4885ITPR1 28/4885ITPR2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.